Real-world data from a comprehensive US Veterans Affairs Health Care system study of 215,970 individuals with type 2 diabetes revealed that GLP-1 medications were associated with reduced rates of neurocognitive disorders, including Alzheimer’s disease (HR 0.88) and dementia (HR 0.92), as well as decreased risks of substance use disorders and seizures [122]. Here, GLP1R is linked to early-onset autosomal dominant Alzheimer disease.